Navigation Links
The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus' Solicitation Efforts
Date:5/7/2009

nclude, among possible avenues, potential partnering and licensure with major pharmaceutical companies. We believe our success will not just be limited to QR-333. The Company has other ethical pharma products in the development pipeline that we are also excited about.

OUR BOARD IS COMMITTED TO ALIGNING EXECUTIVE COMPENSATION WITH STOCKHOLDER

INTERESTS

The results of our core business, COLD-EEZE and its related products, have been hurt recently by a particularly weak cold season. This softness has been felt not just by The Quigley Corporation, but by the entire sector. In response to the current economic downturn and as part of the Company's efforts to reduce costs and align executive performance with stockholder value, the base salaries for Guy J. Quigley, the Company's President and CEO and Charles A. Phillips, the Company's Executive Vice President and Chief Operating Officer have been reduced 18.12% and 18.07%, respectively, for 2009 as part of the Company's overall cost containment efforts amid current market conditions and the continuing global economic challenge. The Compensation Committee has also rescinded the cash-incentive portion of executive bonuses for 2009 such that any performance-based bonuses would be based solely on any increase in the Company's stock price.

KARKUS HAS NO STRATEGIC PLAN FOR YOUR COMPANY

Karkus' proxy materials DO NOT present any plan or functional strategies for The Quigley Corporation. The best he can offer in his proxy materials is a boilerplate agenda which includes reviewing the Company's management, structure and corporate governance policies. This so-called "strategic plan" reflects no knowledge or insight of the Company's business model, products, operations, markets or long-term strategies/objectives. If Karkus and his slate of nominees have no specific plans for your company, should you simpl
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. The Quigley Corporation Reports First Quarter 2009 Results
2. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
3. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
4. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
5. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
6. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
7. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
8. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
9. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
10. Service Corporation International Announces First Quarter 2009 Financial Results
11. Providence Service Corporation Announces Record Revenues and Earnings in the First Quarter of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2015)... 2015 Forbes Living is scheduled ... one which is synonymous with clean beaches, sparkling office buildings, ... are major economic influencers in the city on the Pacific ... show are pleased to announce the show will be broadcast ... 3:00 PM PDT. Tune in to find out what the ...
(Date:4/25/2015)... DC (PRWEB) April 26, 2015 The ... Seniors (ACE.S) , a national endeavor to prepare nurses ... adults, is a great success, according to a new ... the program's original funding partners. , The project ... of Philadelphia (CCP), under the direction of Elaine Tagliareni, ...
(Date:4/25/2015)... April 25, 2015 In observance of ... join The Million Nets Pledge, a two-year pledge by ... protect refugee families with one million bednets by 2016. ... work with UN partners to protect children, refugees, and ... , “There has been a large surge in ...
(Date:4/25/2015)... New York (PRWEB) April 25, 2015 ... established for vaginal mesh lawsuits filed against C.R. ... U.S. District Court, Southern District of West Virginia. ... a Scheduling Conference was convened that day, after ... Master Long Form Complaint. The Order directed that ...
(Date:4/25/2015)... Henderson, NV (PRWEB) April 25, 2015 ... Program is still eliciting the excitement of the public ... well into the months of May and June. ... Wellness™ held their biannual tradition of "Special Prayers." More ... who had attended previous Special Prayers and have reported ...
Breaking Medicine News(10 mins):Health News:Forbes Living TV Will Air in San Diego, California 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 4Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3
... HealthDay Reporter , WEDNESDAY, Nov. 17 (HealthDay News) ... appear to be at higher risk for heart disease. ... with severe atherosclerosis (hardening of the arteries), as measured ... The condition "is emerging as a significant risk ...
... -- Resistance exercise such as weight training affects blood ... benefits, finds a new study. Researchers at the ... (vascular) responses to two types of moderate-intensity workouts: three ... 30 minutes of aerobic cycling. There were significant ...
... named Walter and Eliza Hall Institute researcher Dr Benjamin Kile ... Minister,s Prize for Life Scientist of the Year is awarded ... the potential to advance, human welfare. Dr Kile, ... be presented with the award tonight by the Hon. Kim ...
... Minn. -- With the 2010 election over and new ... to continue the discussion about patient-centered health care. In ... build a high-value health care system, the Mayo Clinic ... entitled "Achieving the Vision: Advancing High-Value ,Health Care." ...
... , WEDNESDAY, Nov. 17 (HealthDay News) -- The structure of ... researchers say. In their study, the investigators found that ... mammals compared to others and that the difference in growth ... the way it connects the mother and baby. The ...
... N.Y., Nov. 17, 2010 Eight states earned a better grade ... 32 others and the District of Columbia saw their preterm birth ... nation saw the first two-year decline in the preterm birth rate, ... rate dropped to 12.3 percent, from the 2006 final rate of ...
Cached Medicine News:Health News:Veterans With PTSD May Be at Higher Risk for Heart Disease 2Health News:Veterans With PTSD May Be at Higher Risk for Heart Disease 3Health News:Resistance Exercise May Offer Different Cardio Benefits 2Health News:Dr. Benjamin Kile named 2010 Australian Life Scientist of the Year 2Health News:Gestational Period Depends on Structure of Placenta: Research 2Health News:Preterm birth rates improve in most states 2
(Date:4/23/2015)...  AbbVie (NYSE: ABBV ) has announced that ... its New Drug Application (NDA) and granted priority review ... of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The ... genotype 4 (GT4) hepatitis C virus (HCV) infection. ... being evaluated by the FDA for patients in ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
(Date:4/23/2015)... FRANCISCO , April 23, 2015 Nektar Therapeutics ... the first quarter ended March 31, 2015 on Thursday, April ... Howard Robin , president and chief executive officer, will host ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... the conference call can be accessed through a link that ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company ... from its consumer trial with Allumera™, a breakthrough cosmetic ... The RevitAll study was performed with a standard ... Allumera™ improves skin appearance, when compared to exposure by ...
... Inc. (Hologic or the Company) (Nasdaq: ... of premium diagnostics products, medical imaging systems and ... of women, announced today the U.S. Food and ... Makena™ (hydroxyprogesterone caproate injection), formerly known as Gestiva™. ...
Cached Medicine Technology:Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 2Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 3Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 4FDA Approves Hologic's Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical 2
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Lyphochek Benzo/TCA Control Set A is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and tricyclic antidepressant drugs....
Lyphochek Benzo/TCA Control Set B is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and antidepressant drugs....
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Medicine Products: